Biblioteca Humberto Rosselli Quijano
Información del autor
Documentos disponibles escritos por este autor (1)
Refinar búsqueda
[artículo]
| Título : |
Efficacy and safety of asenapine in a placebo- and haloperidol controlled trial in patients with acute exacerbation of schizophrenia |
| Tipo de documento: |
texto impreso |
| Autores: |
John M. Kane, Autor ; Michael Cohen, Autor ; Jun Zhao, Autor |
| Fecha de publicación: |
2022 |
| Artículo en la página: |
pp. 106-115 |
| Idioma : |
Inglés (eng) Idioma original : Inglés (eng) |
| Palabras clave: |
Asenapina, Eficacia, Haloperidol, Seguridad, Esquizofrenia |
| Resumen: |
Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features. In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or haloperidol at 4 mg BID (to verify assay sensitivity). |
| Link: |
./index.php?lvl=notice_display&id=29455 |
in Journal of Clinical Psychopharmacology > Año 2010 - Vol. 30 - No. 2 (Abril) . - pp. 106-115
[artículo] Efficacy and safety of asenapine in a placebo- and haloperidol controlled trial in patients with acute exacerbation of schizophrenia [texto impreso] / John M. Kane, Autor ; Michael Cohen, Autor ; Jun Zhao, Autor . - 2022 . - pp. 106-115. Idioma : Inglés ( eng) Idioma original : Inglés ( eng) in Journal of Clinical Psychopharmacology > Año 2010 - Vol. 30 - No. 2 (Abril) . - pp. 106-115
| Palabras clave: |
Asenapina, Eficacia, Haloperidol, Seguridad, Esquizofrenia |
| Resumen: |
Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features. In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or haloperidol at 4 mg BID (to verify assay sensitivity). |
| Link: |
./index.php?lvl=notice_display&id=29455 |
|
